THER — Theralink Technologies Income Statement
0.000.00%
Last trade - 00:00- $0.62m
- $23.20m
- $0.61m
Annual income statement for Theralink Technologies, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.181 | 0.506 | 0.568 | 0.607 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.129 | 0.388 | 0.343 | 0.481 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.85 | 3.37 | 5.83 | 12.2 | 15.2 |
| Operating Profit | -1.85 | -3.19 | -5.33 | -11.6 | -14.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.4 | -3.17 | -5.47 | -12.7 | -30.9 |
| Net Income After Taxes | -9.4 | -3.17 | -5.47 | -12.7 | -30.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.4 | -3.17 | -5.47 | -12.7 | -30.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.4 | -5.18 | -6.64 | -13 | -30.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -18.8 | -0.063 | -0.001 | -0.002 | -0.004 |